Abstract
Cetuximab (ERBITUX®), an anti-EGFR monoclonal antibody, has been approved for the treatment of metastatic colorectal cancer (mCRC). The pharmacokinetics (PK) of cetuximab has a nonlinear elimination due to the turnover of EGFR. (1) Target-mediated drug disposition (TMDD) models (2,3) have been commonly used to describe target-mediated pharmacokinetics (TMPK) of monoclonal antibodies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
